Re-Entering Antibacterial Drug Development Summit

Several factors including diminishing financial return, lack of new discovery platforms and others, had a cooling effect on pharmaceutical companies' activity in the area of antibacterial drug development. At the same time, we are witnessing the wide spread of resistant bacteria, leading to untreatable infections. "We are facing a huge crisis worldwide not having an antibiotics pipeline," said Dr. Janet Woodcock, Director of CDER at FDA, in her recent interview to NYT. The governments of European countries and the United States have created several incentives for the industry to rise to the challenge. Therefore, many companies are exploring the opportunities to start or re-open their antibacterial departments, or to stimulate the existing research and development. Cambridge Healthtech Institute is pleased to present its inaugural Re-Entering Antibacterial Drug Development Summit that includes a science track and a business track, and features a wide range of pivotal issues. The Summit is designed as a forum for knowledge and opinion exchange between the major stakeholders shaping the current state of antibacterial discovery and development.